Data from COVID-19 patients who received Gilead Sciences Inc.’s experimental drug remdesivir under individual “compassionate use” programs shows most patients improved, but the drug developer and other experts say it is difficult to draw conclusions fr… […]
HIV patients could one day replace a daily pill for one that would last a week or more, should a new drug development deal struck this week prove successful.
Foster City-based Gilead Sciences Inc. (Nasdaq: GILD) is enlisting Massachusetts startup Lynd… […]
The marquee drug in the fight against Covid-19 helped most “moderate” Covid pneumonia patients improve after five days but those treated over 10 days did not see an improvement that was statistically significant.
Covid pneumonia patients who didn’t re… […]